3.連結財務諸表及び主な注記
(1)連結財政状態計算書
| | | (単位:百万円) |
| 前連結会計年度末 (2024年3月31日) | | 当連結会計年度末 (2025年3月31日) |
資産 | | | |
流動資産 | | | |
現金及び現金同等物 | 58,094 | | 55,241 |
営業債権及びその他の債権 | 47,237 | | 42,292 |
棚卸資産 | 39,111 | | 42,500 |
その他の金融資産 | 10,609 | | 3,244 |
その他の流動資産 | 9,232 | | 6,461 |
流動資産合計 | 164,285 | | 149,740 |
非流動資産 | | | |
有形固定資産 | 33,582 | | 34,531 |
無形資産 | 25,120 | | 48,315 |
使用権資産 | 2,971 | | 2,781 |
その他の金融資産 | 32,862 | | 39,492 |
繰延税金資産 | 1,766 | | 5,597 |
その他の非流動資産 | 2,817 | | 3,177 |
非流動資産合計 | 99,119 | | 133,897 |
資産合計 | 263,404 | | 283,637 |
| | | (単位:百万円) |
| 前連結会計年度末 (2024年3月31日) | | 当連結会計年度末 (2025年3月31日) |
負債及び資本 | | | |
負債 | | | |
流動負債 | | | |
営業債務及びその他の債務 | 24,706 | | 16,857 |
その他の金融負債 | 372 | | 305 |
リース負債 | 1,720 | | 1,348 |
未払法人所得税 | 3,594 | | 4,705 |
その他の流動負債 | 6,941 | | 7,100 |
流動負債合計 | 37,336 | | 30,316 |
非流動負債 | | | |
その他の金融負債 | 232 | | 233 |
リース負債 | 1,152 | | 1,374 |
退職給付に係る負債 | 4,090 | | 4,313 |
その他の非流動負債 | 58 | | 59 |
非流動負債合計 | 5,533 | | 5,980 |
負債合計 | 42,870 | | 36,297 |
資本 | | | |
資本金 | 5,174 | | 5,174 |
資本剰余金 | 4,445 | | 4,491 |
利益剰余金 | 198,260 | | 222,640 |
自己株式 | △2,480 | | △2,459 |
その他の資本の構成要素 | 14,825 | | 17,181 |
親会社の所有者に帰属する持分合計 | 220,224 | | 247,028 |
非支配持分 | 310 | | 312 |
資本合計 | 220,534 | | 247,340 |
負債及び資本合計 | 263,404 | | 283,637 |
E0093145160日本新薬株式会社通期第3号参考様式 [IFRS](連結)IFRStrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse451602023-04-012024-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-04-012024-03-31jpigp_cor:TreasurySharesIFRSMember451602023-04-012024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-04-012024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-04-012024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-04-012024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602023-04-012024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-03-31jpigp_cor:ShareCapitalIFRSMember451602023-03-31jpigp_cor:CapitalSurplusIFRSMember451602023-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-03-31jpigp_cor:TreasurySharesIFRSMember451602023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602023-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012024-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-05-08451602025-03-31451602024-04-012025-03-31451602024-03-31451602023-04-012024-03-31451602023-03-31451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012025-03-31jpigp_cor:ShareCapitalIFRSMember451602024-04-012025-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-04-012025-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-04-012025-03-31jpigp_cor:TreasurySharesIFRSMember451602024-04-012025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602024-04-012025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-04-012024-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpcrp_cor:ReportableSegmentsMember451602025-03-31tse-acediffr-45160:PharmaceuticalsMember451602025-03-31tse-acediffr-45160:FunctionalFoodMember451602025-03-31jpcrp_cor:ReconcilingItemsMember451602024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember451602024-04-012025-03-31tse-acediffr-45160:PharmaceuticalsMember451602024-04-012025-03-31tse-acediffr-45160:FunctionalFoodMember451602024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember451602024-03-31jpcrp_cor:ReportableSegmentsMember451602024-03-31tse-acediffr-45160:PharmaceuticalsMember451602024-03-31tse-acediffr-45160:FunctionalFoodMember451602024-03-31jpcrp_cor:ReconcilingItemsMember451602023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember451602023-04-012024-03-31tse-acediffr-45160:PharmaceuticalsMember451602023-04-012024-03-31tse-acediffr-45160:FunctionalFoodMember451602023-04-012024-03-31jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:sharesxbrli:pureiso4217:JPY